Annual Current Liabilities
$99.38 M
+$21.90 M+28.26%
December 31, 2023
Summary
- As of February 7, 2025, PBYI annual total current liabilities is $99.38 million, with the most recent change of +$21.90 million (+28.26%) on December 31, 2023.
- During the last 3 years, PBYI annual current liabilities has fallen by -$14.87 million (-13.02%).
- PBYI annual current liabilities is now -13.02% below its all-time high of $114.25 million, reached on December 31, 2020.
Performance
PBYI Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$110.40 M
+$6.10 M+5.85%
September 30, 2024
Summary
- As of February 7, 2025, PBYI quarterly total current liabilities is $110.40 million, with the most recent change of +$6.10 million (+5.85%) on September 30, 2024.
- Over the past year, PBYI quarterly current liabilities has increased by +$43.03 million (+63.89%).
- PBYI quarterly current liabilities is now -21.37% below its all-time high of $140.41 million, reached on March 31, 2021.
Performance
PBYI Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
PBYI Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +28.3% | +63.9% |
| 3 y3 years | -13.0% | +94.2% |
| 5 y5 years | +48.1% | +94.2% |
PBYI Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -9.3% | +28.3% | at high | +129.1% |
| 5 y | 5-year | -13.0% | +28.3% | -21.4% | +129.1% |
| alltime | all time | -13.0% | -100.0% | -21.4% | -100.0% |
Puma Biotechnology Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $110.40 M(+5.8%) |
| Jun 2024 | - | $104.30 M(+6.2%) |
| Mar 2024 | - | $98.19 M(-1.2%) |
| Dec 2023 | $99.38 M(+28.3%) | $99.38 M(+47.5%) |
| Sep 2023 | - | $67.36 M(+11.7%) |
| Jun 2023 | - | $60.29 M(+25.1%) |
| Mar 2023 | - | $48.19 M(-37.8%) |
| Dec 2022 | $77.48 M(-29.3%) | $77.48 M(+29.2%) |
| Sep 2022 | - | $59.99 M(+5.5%) |
| Jun 2022 | - | $56.83 M(-24.0%) |
| Mar 2022 | - | $74.79 M(-31.8%) |
| Dec 2021 | $109.59 M(-4.1%) | $109.59 M(-5.7%) |
| Sep 2021 | - | $116.26 M(-15.7%) |
| Jun 2021 | - | $137.90 M(-1.8%) |
| Mar 2021 | - | $140.41 M(+22.9%) |
| Dec 2020 | $114.25 M(+25.8%) | $114.25 M(-3.3%) |
| Sep 2020 | - | $118.20 M(+25.0%) |
| Jun 2020 | - | $94.53 M(+4.5%) |
| Mar 2020 | - | $90.47 M(-0.4%) |
| Dec 2019 | $90.84 M(+35.3%) | $90.84 M(+2.8%) |
| Sep 2019 | - | $88.34 M(-3.6%) |
| Jun 2019 | - | $91.66 M(-9.6%) |
| Mar 2019 | - | $101.40 M(+51.1%) |
| Dec 2018 | $67.11 M(+15.0%) | $67.11 M(+16.0%) |
| Sep 2018 | - | $57.88 M(-8.9%) |
| Jun 2018 | - | $63.53 M(+9.3%) |
| Mar 2018 | - | $58.12 M(-0.4%) |
| Dec 2017 | $58.34 M(+55.7%) | $58.34 M(-40.0%) |
| Sep 2017 | - | $97.25 M(+105.9%) |
| Jun 2017 | - | $47.24 M(+8.0%) |
| Mar 2017 | - | $43.73 M(+16.7%) |
| Dec 2016 | $37.46 M | $37.46 M(-0.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2016 | - | $37.60 M(-3.5%) |
| Jun 2016 | - | $38.97 M(+0.2%) |
| Mar 2016 | - | $38.91 M(+19.9%) |
| Dec 2015 | $32.44 M(-27.0%) | $32.44 M(+28.1%) |
| Sep 2015 | - | $25.33 M(-2.9%) |
| Jun 2015 | - | $26.10 M(+0.1%) |
| Mar 2015 | - | $26.08 M(-41.3%) |
| Dec 2014 | $44.44 M(+130.6%) | $44.44 M(+51.4%) |
| Sep 2014 | - | $29.36 M(+5.1%) |
| Jun 2014 | - | $27.93 M(+38.0%) |
| Mar 2014 | - | $20.24 M(+5.0%) |
| Dec 2013 | $19.27 M(-11.2%) | $19.27 M(+0.2%) |
| Sep 2013 | - | $19.23 M(-3.0%) |
| Jun 2013 | - | $19.82 M(-8.3%) |
| Mar 2013 | - | $21.63 M(-0.3%) |
| Dec 2012 | $21.70 M(+3596.9%) | $21.70 M(-18.6%) |
| Sep 2012 | - | $26.66 M(+71.5%) |
| Jun 2012 | - | $15.54 M(+63.9%) |
| Mar 2012 | - | $9.48 M(+1515.5%) |
| Dec 2011 | $587.00 K(>+9900.0%) | $587.00 K(>+9900.0%) |
| Sep 2011 | - | $0.00(-100.0%) |
| Jun 2011 | - | $3300.00(+37.5%) |
| Mar 2011 | - | $2400.00(>+9900.0%) |
| Dec 2010 | $0.00(-100.0%) | $0.00(0.0%) |
| Sep 2010 | - | $0.00(0.0%) |
| Jun 2010 | - | $0.00(0.0%) |
| Mar 2010 | - | $0.00(-100.0%) |
| Dec 2009 | $2300.00(+4.5%) | $2300.00(>+9900.0%) |
| Sep 2009 | - | $0.00(-100.0%) |
| Jun 2009 | - | $2300.00(+360.0%) |
| Mar 2009 | - | $500.00(-77.3%) |
| Dec 2008 | $2200.00 | $2200.00 |
FAQ
- What is Puma Biotechnology annual total current liabilities?
- What is the all time high annual current liabilities for Puma Biotechnology?
- What is Puma Biotechnology annual current liabilities year-on-year change?
- What is Puma Biotechnology quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Puma Biotechnology?
- What is Puma Biotechnology quarterly current liabilities year-on-year change?
What is Puma Biotechnology annual total current liabilities?
The current annual current liabilities of PBYI is $99.38 M
What is the all time high annual current liabilities for Puma Biotechnology?
Puma Biotechnology all-time high annual total current liabilities is $114.25 M
What is Puma Biotechnology annual current liabilities year-on-year change?
Over the past year, PBYI annual total current liabilities has changed by +$21.90 M (+28.26%)
What is Puma Biotechnology quarterly total current liabilities?
The current quarterly current liabilities of PBYI is $110.40 M
What is the all time high quarterly current liabilities for Puma Biotechnology?
Puma Biotechnology all-time high quarterly total current liabilities is $140.41 M
What is Puma Biotechnology quarterly current liabilities year-on-year change?
Over the past year, PBYI quarterly total current liabilities has changed by +$43.03 M (+63.89%)